CY1120536T1 - Μεθοδος και συνθεσεις για τη θεραπευτικη αγωγη του καρκινου - Google Patents
Μεθοδος και συνθεσεις για τη θεραπευτικη αγωγη του καρκινουInfo
- Publication number
- CY1120536T1 CY1120536T1 CY20181100285T CY181100285T CY1120536T1 CY 1120536 T1 CY1120536 T1 CY 1120536T1 CY 20181100285 T CY20181100285 T CY 20181100285T CY 181100285 T CY181100285 T CY 181100285T CY 1120536 T1 CY1120536 T1 CY 1120536T1
- Authority
- CY
- Cyprus
- Prior art keywords
- compositions
- health education
- cancer health
- cancer
- subject
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 150000001495 arsenic compounds Chemical class 0.000 abstract 2
- 231100000433 cytotoxic Toxicity 0.000 abstract 2
- 230000001472 cytotoxic effect Effects 0.000 abstract 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 229960003668 docetaxel Drugs 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3998708P | 2008-03-27 | 2008-03-27 | |
| US12/408,864 US20090246291A1 (en) | 2008-03-27 | 2009-03-23 | Method and compositions for treatment of cancer |
| PCT/US2009/038104 WO2009120697A2 (en) | 2008-03-27 | 2009-03-24 | Method and compositions for treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1120536T1 true CY1120536T1 (el) | 2019-07-10 |
Family
ID=41114644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20181100285T CY1120536T1 (el) | 2008-03-27 | 2018-03-09 | Μεθοδος και συνθεσεις για τη θεραπευτικη αγωγη του καρκινου |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20090246291A1 (enExample) |
| EP (1) | EP2268292B1 (enExample) |
| JP (2) | JP5543956B2 (enExample) |
| KR (1) | KR101634138B1 (enExample) |
| CN (2) | CN102046187A (enExample) |
| AU (1) | AU2009228378B2 (enExample) |
| BR (1) | BRPI0909164A2 (enExample) |
| CA (1) | CA2719766C (enExample) |
| CY (1) | CY1120536T1 (enExample) |
| DK (1) | DK2268292T3 (enExample) |
| ES (1) | ES2656762T3 (enExample) |
| HU (1) | HUE036609T2 (enExample) |
| LT (1) | LT2268292T (enExample) |
| MX (1) | MX2010010621A (enExample) |
| PL (1) | PL2268292T3 (enExample) |
| PT (1) | PT2268292T (enExample) |
| RU (1) | RU2508116C2 (enExample) |
| SI (1) | SI2268292T1 (enExample) |
| WO (1) | WO2009120697A2 (enExample) |
| ZA (1) | ZA201006988B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1721615A1 (en) | 2005-05-09 | 2006-11-15 | Komipharm International Co., Ltd. | Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis |
| US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
| PL2475362T3 (pl) * | 2009-09-10 | 2019-09-30 | Kominox, Inc. | Terapia celowana w nowotworowe komórki macierzyste i raka lekoopornego |
| US8795738B2 (en) * | 2009-11-12 | 2014-08-05 | Board Of Regents Of The University Of Texas System | Use of arsenic for cancer therapy protection |
| US11084811B2 (en) | 2010-03-01 | 2021-08-10 | Oncternal Therapeutics, Inc. | Compounds for treatment of cancer |
| WO2012012305A2 (en) * | 2010-07-18 | 2012-01-26 | Niiki Pharma Inc. | Combination therapy using a ruthenium complex |
| MX336761B (es) * | 2010-08-24 | 2016-01-29 | Univ Tennessee Res Foundation | Compuestos para el tratamiento de cancer. |
| WO2012131487A2 (en) * | 2011-03-30 | 2012-10-04 | Kominox, Inc. | Compositions and methods for the treatment of cancer |
| US8834938B2 (en) | 2011-05-18 | 2014-09-16 | Board Of Regents Of The University Of Texas System | Use of arsenic for cancer therapy protection |
| WO2012155061A1 (en) * | 2011-05-12 | 2012-11-15 | Board Of Regents, University Of Texas System | Use of arsenic for cancer therapy protection |
| KR101309844B1 (ko) | 2013-03-15 | 2013-09-23 | 박상채 | 항암 활성 증진용 한약재 및 이의 제조방법 |
| US20160184356A1 (en) * | 2013-03-15 | 2016-06-30 | Ke Jian Jim Liu | Arsenic-based treatment of cancers and inflammatory disorders |
| AU2014290012B2 (en) * | 2013-07-19 | 2020-01-16 | Onyx Therapeutics, Inc. | Peptide epoxyketone proteasome inhibitors in combination with PIM kinase inhibitors for treatment of cancers |
| AU2017368444B9 (en) | 2016-12-01 | 2020-07-02 | Eupharma Pty Ltd | Arsenic compositions |
| CA3094115A1 (en) | 2018-03-22 | 2019-09-26 | Komipharm International Australia Pty Ltd | Pharmaceutical composition comprising meta arsenite and method of manufacture |
| CN116236505A (zh) * | 2023-03-15 | 2023-06-09 | 上海市第四人民医院 | 三氧化二砷在制备肺神经内分泌癌治疗药物中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1391206B1 (en) * | 1997-10-15 | 2008-07-02 | Polarx Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising arsenic trioxide for the treatment of non-Hodgkin's lymphoma |
| IL136051A0 (en) * | 1997-11-10 | 2001-05-20 | Sloan Kettering Inst Cancer | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
| KR20020083678A (ko) * | 2001-04-28 | 2002-11-04 | 주식회사 한국미생물연구소 | 아르세닉산나트륨 염, 소디움 메타아르세나이트 또는 이의혼합물을 함유한 항암제 조성물 |
| ES2944907T3 (es) * | 2002-04-10 | 2023-06-27 | Komipharm Int Co Ltd | Uso de meta-arsenito de sodio para el tratamiento de tumores |
| EP1721615A1 (en) * | 2005-05-09 | 2006-11-15 | Komipharm International Co., Ltd. | Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis |
| US8097237B2 (en) * | 2005-08-23 | 2012-01-17 | Stc.Unm | Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma |
| WO2009049258A1 (en) * | 2007-10-12 | 2009-04-16 | The Johns Hopkins University | Compounds for hedgehog pathway blockade in proliferative disorders, including hematopoietic malignancies |
-
2009
- 2009-03-23 US US12/408,864 patent/US20090246291A1/en not_active Abandoned
- 2009-03-24 SI SI200931809T patent/SI2268292T1/en unknown
- 2009-03-24 CA CA2719766A patent/CA2719766C/en active Active
- 2009-03-24 PL PL09723788T patent/PL2268292T3/pl unknown
- 2009-03-24 RU RU2010143893/15A patent/RU2508116C2/ru active
- 2009-03-24 MX MX2010010621A patent/MX2010010621A/es active IP Right Grant
- 2009-03-24 EP EP09723788.7A patent/EP2268292B1/en active Active
- 2009-03-24 DK DK09723788.7T patent/DK2268292T3/en active
- 2009-03-24 KR KR1020107024132A patent/KR101634138B1/ko not_active Expired - Fee Related
- 2009-03-24 JP JP2011501983A patent/JP5543956B2/ja not_active Expired - Fee Related
- 2009-03-24 ES ES09723788.7T patent/ES2656762T3/es active Active
- 2009-03-24 LT LTEP09723788.7T patent/LT2268292T/lt unknown
- 2009-03-24 BR BRPI0909164A patent/BRPI0909164A2/pt not_active Application Discontinuation
- 2009-03-24 AU AU2009228378A patent/AU2009228378B2/en not_active Ceased
- 2009-03-24 PT PT97237887T patent/PT2268292T/pt unknown
- 2009-03-24 CN CN2009801187686A patent/CN102046187A/zh active Pending
- 2009-03-24 HU HUE09723788A patent/HUE036609T2/hu unknown
- 2009-03-24 CN CN201510355863.5A patent/CN104997808A/zh active Pending
- 2009-03-24 WO PCT/US2009/038104 patent/WO2009120697A2/en not_active Ceased
-
2010
- 2010-09-30 ZA ZA2010/06988A patent/ZA201006988B/en unknown
-
2014
- 2014-03-10 JP JP2014046212A patent/JP2014101387A/ja not_active Withdrawn
-
2017
- 2017-06-02 US US15/613,020 patent/US20180055812A1/en not_active Abandoned
-
2018
- 2018-03-09 CY CY20181100285T patent/CY1120536T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2268292A4 (en) | 2011-05-11 |
| LT2268292T (lt) | 2018-03-26 |
| PL2268292T3 (pl) | 2018-06-29 |
| RU2010143893A (ru) | 2012-05-10 |
| WO2009120697A2 (en) | 2009-10-01 |
| AU2009228378B2 (en) | 2014-07-17 |
| DK2268292T3 (en) | 2018-03-12 |
| EP2268292A2 (en) | 2011-01-05 |
| JP2014101387A (ja) | 2014-06-05 |
| BRPI0909164A2 (pt) | 2016-06-21 |
| ES2656762T3 (es) | 2018-02-28 |
| MX2010010621A (es) | 2011-04-05 |
| JP2011515481A (ja) | 2011-05-19 |
| EP2268292B1 (en) | 2017-12-27 |
| HUE036609T2 (hu) | 2018-07-30 |
| SI2268292T1 (en) | 2018-03-30 |
| CA2719766A1 (en) | 2009-10-01 |
| AU2009228378A1 (en) | 2009-10-01 |
| CN102046187A (zh) | 2011-05-04 |
| ZA201006988B (en) | 2012-05-30 |
| WO2009120697A4 (en) | 2010-04-15 |
| PT2268292T (pt) | 2018-02-19 |
| JP5543956B2 (ja) | 2014-07-09 |
| WO2009120697A3 (en) | 2010-02-18 |
| US20180055812A1 (en) | 2018-03-01 |
| KR20110009664A (ko) | 2011-01-28 |
| US20090246291A1 (en) | 2009-10-01 |
| KR101634138B1 (ko) | 2016-06-28 |
| CN104997808A (zh) | 2015-10-28 |
| RU2508116C2 (ru) | 2014-02-27 |
| CA2719766C (en) | 2017-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125772T1 (el) | Μακροκυκλικες ενωσεις για τη θεραπευτικη αντιμετωπιση νοσων | |
| CY1120555T1 (el) | Νανοσωματιδιο που περιλαμβανει ραπαμυκινη και αλβουμινη ως αντικαρκινικος παραγοντας | |
| CY1118216T1 (el) | Μεθοδοι αγωγης καρκινου | |
| CY1125077T1 (el) | Αγωγη της ανεπαρκειας και ελλειψης βιταμινης d με 25-υδροξυβιταμινη d2 και 25-υδροξυβιταμινη d3 | |
| CL2019000221A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1. | |
| NZ752526A (en) | Pyrrolobenzodiazepine conjugates | |
| BR112014021498A2 (pt) | composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado | |
| CY1120102T1 (el) | Συνθεσεις και μεθοδοι για μειωση τριγλυκεριδιων χωρις αυξηση επιπεδων ldl-c σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης | |
| CL2018002291A1 (es) | Anticuerpos anti-fgfr2iiib afucosilados (divisional solicitud 201600221) | |
| CY1117869T1 (el) | Φαρμακοτεχνικες μορφες για απο του στοματος απελευθερωση προσροφητικων στο εντερο | |
| CY1122074T1 (el) | Νεα παραγωγα 3'-δεοξυαδενοσινης του φωσφοραμαδικου εστερα toy 2' και/η 5' aminoξεος ως αντικαρκινικες ενωσεις | |
| MX370662B (es) | Composiciones que comprenden nanopartículas de paclitaxel y albúmina para usarse en el tratamiento de cáncer. | |
| CY1123490T1 (el) | Συνθεσεις που προερχονται απο χιτοζανη | |
| PH12012502399A1 (en) | Combination therapy methods for treating proliferative diseases | |
| EA201300242A1 (ru) | Фармацевтические композиции, содержащие замещенные ациланилиды | |
| MX381017B (es) | Compuestos peptidomiméticos y conjugados anticuerpo-fármaco de estos. | |
| CY1124529T1 (el) | Ενωσεις λευκοχρυσου λειτουργικοποιημενες με μονομηλεινιμιδιο για θεραπεια καρκινου | |
| UY36075A (es) | Derivados de tubulisina | |
| CY1113640T1 (el) | Μεθοδοι για την θεραπευτικη αγωγη ρευματοειδους αρθριτιδας | |
| WO2009120697A3 (en) | Method and compositions for treatment of cancer | |
| CY1118081T1 (el) | Παρασκευασματα συνδυασμου με εξωσωματα και κορτικοστεροειδες | |
| CY1122968T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει μια ενωση διαμινο-ετεροκυκλικου καρβοξαμιδιου ως δραστικο συστατικο | |
| EA201690085A1 (ru) | Полимерные наночастицы доцетаксела для лечения рака | |
| CY1122998T1 (el) | Μεθοδοι και συνθεσεις για την αντιμετωπιση της καταθλιψης χρησιμοποιωντας κυκλοβενζαπρινη | |
| EA201891473A1 (ru) | Комбинированная терапия |